Paper ET23

eProtocol and the Promise of Automation

Bill Qubeck, Sycamore Informatics, Cary, NC
Suhas Giriraj, Sycamore Informatics, Bengaluru, India

ABSTRACT
The eProtocol initiative represents a significant advancement in the automation of clinical trial processes, facilitating streamlined protocol design, execution, and monitoring. By digitizing traditionally manual tasks, eProtocol enhances efficiency, reduces human error, and accelerates trial timelines. This abstract explores how eProtocol is transforming the landscape of clinical research by offering a more integrated and automated approach to protocol management. The potential benefits for sponsors, sites, and regulators alike underscore its promise as a cornerstone of modern clinical trials.

INTRODUCTION
The clinical trial industry is undergoing a significant transformation. Traditional protocol development methods—rooted in static documents, manual workflows, and fragmented collaboration—have long been a bottleneck in study execution, leading to delays, increased costs, and regulatory inefficiencies.

Enter eProtocol, a paradigm shift in protocol automation that replaces static documents with machine-readable, structured protocols. By leveraging Structured Protocol Authoring (SPA), Metadata Repositories (MDR), and TransCelerate BioPharma's Digital Data Flow (DDF) initiative, eProtocol promises faster study builds, improved regulatory compliance, and seamless integration with downstream clinical systems.

This article explores the limitations of traditional protocol processes, the power of structured protocol authoring, and the role of metadata-driven automation in shaping the future of clinical trials.

WHAT IS A CLINICAL PROTOCOL?
A clinical protocol is a detailed document that outlines the entire plan of a clinical trial, ensuring the research is conducted in a scientific, ethical, and regulatory-compliant manner. It serves as a blueprint for investigators, sponsors, and regulatory agencies to maintain consistency, safeguard participant safety, and ensure data integrity. According to the International Council for Harmonisation (ICH) E6(R2) Good Clinical Practice (GCP) guidelines, a clinical protocol is defined as:

"A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. The protocol usually also gives the background and rationale for the trial, but these could be provided in other protocol-referenced documents" (ICH, 2022).

This structured document helps researchers avoid bias, standardizes procedures, and facilitates regulatory approvals. Below, we break down each section of a clinical trial protocol, explaining its purpose, structure, and relevance in clinical research. Ten key components of a clinical trial protocol are described below (Examples below are from: https://cdn.clinicaltrials.gov/large-docs/52/NCT03235752/Prot_000.pdf).

1. Synopsis (Summary of the Protocol)
The synopsis provides a high-level summary of the clinical trial, making it easier for stakeholders (regulators, sponsors, and researchers) to grasp key details without reading the entire protocol. This section allows quick reference and comprehension of the study's purpose and execution and typically includes:

- **Study Objectives**: The primary and secondary goals of the trial.
- **Study Design**: Type of trial (e.g., randomized controlled trial, observational study).
- **Participant Population**: Eligibility criteria (inclusion and exclusion).

- **Study Treatment**: The investigational drug or intervention being tested.
- **Endpoints**: The primary and secondary outcomes to be measured.
- **Study Duration**: Expected trial timeline, including recruitment, follow-ups, and data analysis phases.

TJ301 Solution for Injection Clinical Trial Protocol	Protocol No.: CTJ301UC201	Date: 16 May 2017 Ver.1.1 Supersedes: Ver.1.0 Page 6 of 97

SYNOPSIS

TITLE OF TRIAL A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TJ301 (FE 999301) Administered Intravenously in Patients with Active Ulcerative Colitis
Coordinating Investigator Prof. Dr. Minhu Chen Chair, Department of Gastroenterology and Hepatology Vice President The First Affiliated Hospital, Sun Yat-sen University 58 Zhongshan Road, Guangzhou, China
Expert committee Prof. Dr. Stefan Schreiber University Hospital Schleswig-Holstein Arnold-Heller-Str. 3 24105 Kiel Germany
Investigators Multicenter, international across Mainland China, Taiwan, Republic of Korea and Australia.

Example from https://cdn.clinicaltrials.gov/large-docs/52/NCT03235752/Prot_000.pdf

2. Introduction (Background & Rationale)

The introduction sets the stage for the study by explaining why the trial is necessary and what knowledge gaps it seeks to fill. This section ensures that the study has a strong scientific foundation before proceeding to execution and includes:

- **Background Information**: Details about the disease or medical condition being studied.
- **Current Standard of Care**: Available treatment options and their limitations.
- **Justification for the Study**: Why a new approach, drug, or intervention is needed.
- **Preclinical & Clinical Data**: Summary of past research supporting the need for the trial.

3. Objectives and Purpose

The Objectives and Purpose section articulates the fundamental goals of the clinical trial, ensuring that the study is guided by specific, measurable, and clinically relevant questions. The primary objective defines the main outcome the trial aims to evaluate (e.g., whether a new drug reduces disease progression). In contrast, secondary objectives explore additional aspects, such as long-term safety, biomarker responses, or patient-reported quality of life improvements, providing a comprehensive understanding of the intervention's impact. This section is divided into:

- **Primary Objective**: The main question the trial seeks to answer (e.g., Does Drug A reduce symptoms of Disease X?).
- **Secondary Objectives**: Additional questions, such as assessing long-term safety or measuring biomarkers.

4. Study Design

The Study Design section provides a structured framework for how the trial will be conducted, detailing essential elements such as whether the study is randomized, placebo-controlled, single-blind, or double-blind to minimize bias and enhance data validity. Additionally, it describes the phases of the study (Phase I-IV), control groups, stratification methods, and adaptive design elements, ensuring that the research methodology aligns with scientific and regulatory standards while maintaining participant safety. Key aspects include:

- **Type of Study**:
  - **Interventional** (e.g., randomized controlled trial, crossover study).
  - **Observational** (e.g., cohort study, case-control study).
- **Blinding & Randomization**: Methods to reduce bias (single-blind, double-blind).
- **Control Group**: Placebo-controlled or active-comparator groups, if applicable.
- **Phases of the Trial**:
  - **Phase I**: Small sample, safety assessment.
  - **Phase II**: Larger sample, efficacy testing.
  - **Phase III**: Large-scale confirmation study.
  - **Phase IV**: Post-market surveillance.

5. Study Population (Eligibility Criteria)
The Study Population section outlines the criteria that define who can participate in the trial, ensuring a homogeneous and clinically relevant group by setting specific inclusion criteria (e.g., patients within a defined age range, disease severity, or biomarker expression). Simultaneously, exclusion criteria are established to prevent risks to patient safety and eliminate confounding variables, such as individuals with comorbid conditions, concurrent medication use, or a history of adverse reactions to similar treatments. This section includes:

- **Inclusion Criteria**: Participants must meet the requirements (age, disease stage, biomarkers).
- **Exclusion Criteria**: Factors that disqualify individuals (comorbidities, medication use).

6. Study Treatment (Intervention Details)
The Study Treatment section details the investigational product being tested, including its chemical composition, dosage, route of administration (oral, intravenous, etc.), and expected treatment duration to ensure standardized delivery across study sites. Additionally, it outlines procedures for dose escalation, modifications due to adverse events, placebo-controlled comparisons, or combination therapy regimens, ensuring consistency in administration while allowing for necessary adjustments based on safety monitoring. This section outlines:

- **Investigational Product**: The drug, device, or therapy being tested.
- **Dosing Regimen**: Dosage, frequency, and administration route.
- **Duration of Treatment**: How long will participants receive the intervention?

7. Assessments and Endpoints
The Assessments and Endpoints section defines the measurable outcomes that will determine the study's success, distinguishing between primary endpoints (the most critical outcome, such as overall survival or reduction in disease symptoms) and secondary endpoints (additional measures like biomarker levels, patient-reported outcomes, or functional improvements). It also specifies how assessments will be conducted, including laboratory tests, imaging studies, questionnaires, and physician evaluations, ensuring data consistency across all study sites.

- **Primary Endpoint**: The main result used to determine effectiveness (e.g., reduction in disease symptoms).
- **Secondary Endpoints**: Additional measures, such as biomarker changes or side effects.
- **Safety Assessments**: Monitoring for adverse effects through clinical and laboratory tests.

8. Clinical Study Schedule of Activities (SoA)
The Schedule of Activities (SoA) section presents a detailed timeline for all study-related procedures, including participant screening, baseline assessments, treatment administration, follow-up visits, and final evaluations. This structured schedule ensures that every study milestone—from recruitment to data collection—follows a predefined timeframe, allowing for efficient trial management, adherence to regulatory expectations, and standardized patient monitoring across all participating sites.

- **Screening & Enrollment**: How and when participants are recruited.
- **Treatment Visits**: When assessments, blood draws, imaging, or questionnaires occur.

- **Follow-ups**: Post-treatment monitoring for long-term effects.

9. Statistical Analysis Plan
The Statistical Analysis Plan (SAP) provides a detailed methodology for analyzing data, including sample size calculations to ensure statistical power, predefined statistical models, and significance thresholds for primary and secondary outcomes. It also outlines how missing data will be handled, how subgroup analyses will be conducted, and whether any interim analyses will be performed to evaluate safety or efficacy before the study concludes, ensuring the data is interpreted with scientific rigor. It includes:

- **Sample Size Calculation**: Ensuring enough participants to detect meaningful differences.
- **Statistical Tests**: Methods used to analyze primary and secondary endpoints.
- **Handling of Missing Data**: How to address incomplete datasets.

10. Ethical and Regulatory Considerations
The Ethical and Regulatory Considerations section ensures that the trial adheres to global regulatory standards such as ICH-GCP, FDA, and EMA guidelines, emphasizing the importance of ethical conduct, data integrity, and participant safety. It also describes the informed consent process, confidentiality measures, Institutional Review Board (IRB) approvals, and data monitoring committees (DMCs) that oversee compliance, ensuring the rights and well-being of participants are protected throughout the study.

- **Informed Consent Process**: How participant rights and safety are protected.
- **Compliance with ICH-GCP and FDA Regulations**.
- **Data Confidentiality & Monitoring Plans**.

"What is a Clinical Protocol" Summary
A clinical protocol is the backbone of a clinical trial, providing a detailed plan that ensures scientific rigor, participant safety, and regulatory compliance. From defining objectives to outlining ethical considerations, each section plays a crucial role in the success of a study. By following a well-structured protocol, researchers can generate high-quality data that advances medical knowledge while safeguarding participant well-being.

TRADITIONAL PROCESS OF CLINICAL TRIAL PROTOCOL DEVELOPMENT, REVIEW, AND APPROVAL

As described above, the core of every trial is the clinical trial protocol, a highly detailed document that outlines the study's objectives, design, methodology, statistical considerations, and ethical standards. Despite its importance, the traditional process of protocol development, review, and approval is highly complex and time-consuming, involving numerous stakeholders, including clinical researchers, regulatory bodies, biostatisticians, data management teams, and ethics committees. Traditionally, Microsoft Word and PDF documents are used to author, review, comment, and distribute the protocol, leading to multiple document versions, version control issues, and inefficiencies (Lindus Health, 2023). These files must be stored, shared, and managed among numerous teams, leading to potential data fragmentation, miscommunication, and extended approval timelines.

1. Conceptualization and Study Design
The development of a clinical trial protocol begins with identifying a medical question or hypothesis that addresses an unmet clinical need. This phase requires collaboration among clinical researchers, medical scientists, epidemiologists, and biostatisticians. These experts work together to define the research objectives, ensuring they are scientifically valid and operationally feasible. During the study design phase, the research team determines:

- The type of study (e.g., randomized controlled trial, observational study).
- The target patient population, with inclusion and exclusion criteria.
- The primary and secondary study endpoints measure treatment efficacy and safety.
- The duration of the study and the number of patient visits.

Statisticians are involved early in the process, ensuring that the sample size calculations provide sufficient statistical power to detect meaningful treatment effects. Meanwhile, clinical operations teams assess the study's practicality, considering aspects such as site availability, patient recruitment feasibility, and geographical distribution (UCSF, 2022).

2. Protocol Authoring

The protocol authoring process is led by clinical scientists, medical writers, and regulatory specialists who work together to create the first draft of the protocol document. This document includes essential sections as described above, but summarized here:

- **Study Objectives** – A clear articulation of what the trial aims to achieve.
- **Study Design** – A detailed description of the methodology, including randomization procedures, blinding, and control groups.
- **Participant Selection** – Inclusion and exclusion criteria to define a homogeneous patient population.
- **Intervention Details** – Information on the investigational drug, its dosage, administration route, and expected duration of treatment.
- **Assessment Methods** – Plans for measuring outcomes, such as clinical assessments, laboratory tests, and imaging studies.
- **Statistical Analysis Plan (SAP)** – The mathematical framework for analyzing trial results, including sample size calculations, statistical tests, and data handling procedures.
- **Ethical and Safety Considerations** – Description of the informed consent process and plans for monitoring patient safety.

Traditionally, this entire document is drafted in Microsoft Word, creating challenges related to version control, collaboration, and document tracking. Changes must be manually incorporated, and feedback is provided using comments and tracked changes. This manual process makes collaboration cumbersome, as different teams edit different versions simultaneously, leading to delays and inconsistencies (FDA, 2023).

3. Internal Review and Stakeholder Collaboration

After drafting, the protocol undergoes rigorous internal review, with multiple teams providing input to refine and improve the document. Clinical operations teams, regulatory affairs specialists, biostatisticians, and data management experts each review the protocol based on their area of expertise.

The clinical operations team evaluates whether the study design is logistically feasible, ensuring that trial sites have the necessary infrastructure, staffing, and patient population to conduct the study. Regulatory affairs specialists verify that the protocol aligns with FDA, EMA, MHRA, and ICH-GCP regulations (ICH, 2016). Biostatisticians review the statistical methodology to ensure validity, accuracy, and compliance with global data standards. The data management team develops a Data Management Plan (DMP) to track, store, and safeguard data throughout the study (Lindus Health, 2023).

Because most protocol versions are shared as Word or PDF files, managing comments and revisions is difficult. Stakeholders may review different versions, leading to confusion and unnecessary revisions. With no automated version control, teams must rely on email exchanges and document repositories, such as SharePoint or Dropbox, making tracking changes cumbersome. Once the protocol is finalized internally, it is submitted to external regulatory agencies and ethics committees for official approval.

4. Regulatory and Ethical Approval

The regulatory and ethical approval process is essential to ensure that the study is safe, ethical, and scientifically justified. The protocol is submitted to Institutional Review Boards (IRBs) and Ethics Committees (ECs), which review:

- The informed consent process ensures patients understand study's risks and benefits.
- Ethical considerations and patient safety monitoring procedures.

- Compliance with international guidelines such as GCP and the Helsinki Declaration (FDA, 2023).

Regulatory agencies, such as the FDA, EMA, and PMDA (Japan Pharmaceuticals and Medical Devices Agency), assess the scientific validity, safety profile, and statistical soundness of the trial design. If concerns arise, sponsors must revise and resubmit the protocol, leading to delays (UCSF, 2022).

This phase can be highly iterative, requiring sponsors to respond to inquiries, modify protocol sections, and submit amendments before receiving final approval. The back-and-forth communication is traditionally handled through email and document attachments, further slowing down the process.

5. Final Approval and Trial Initiation

Once all regulatory approvals are obtained, the protocol is finalized and distributed to trial sites, investigators, and contract research organizations (CROs). Clinical investigators receive training on the study procedures, often via site initiation visits (SIVs), webinars, or online training portals. At this stage, trial sites begin patient recruitment and data collection. Technologies facilitate this process:

- **Clinical Trial Management Systems (CTMS)** for trial tracking and compliance monitoring.
- **Electronic Data Capture (EDC) systems** for real-time data collection and patient safety monitoring.
- **Electronic Trial Master File (eTMF) systems** for document storage, regulatory submissions, and compliance tracking (BioSpace, 2023).

Common Functions/Roles and Brief Description

The following table summarizes the traditional pharmaceutical company functions involved in authoring, reviewing, and finalizing a clinical trial protocol.

Role	Brief Description
Clinical Scientists and Medical Experts	These individuals provide the scientific foundation for the trial, defining the research hypothesis, objectives, and endpoints. Their expertise ensures that the study addresses pertinent clinical questions and meets current medical standards.
Clinical Operations Team	This team is responsible for the logistical aspects of the trial and designs the study's operational framework, including site selection, patient recruitment strategies, and monitoring plans. Their input ensures that the trial is feasible and efficiently executable.
Regulatory Affairs Team	This team ensures the protocol complies with all applicable regulatory requirements, facilitating submissions to health authorities and ethics committees. Their oversight is crucial for securing the necessary approvals to initiate the trial.
Biostatisticians	Experts in statistical methodologies, biostatisticians develop the trial's statistical analysis plan, determining sample sizes, randomization techniques, and data analysis strategies. Their work ensures that the study's design is statistically sound and can address the research objectives.
Data Management Team	This team is responsible for designing data collection tools, managing databases, and ensuring data integrity throughout the trial. Their efforts are vital for accurate data capture, storage, and retrieval, which underpin the study's conclusions.

Summary of the Traditional Process of Clinical Trial Protocol Development, Review, and Approval

The traditional process of clinical trial protocol development is essential but fraught with inefficiencies due to manual workflows, regulatory complexities, and version control challenges. Protocol development involves numerous stakeholders, requiring extensive collaboration, internal reviews, and external approvals. Despite modern clinical trial technologies, protocol documents are still authored, edited, and distributed using Microsoft Word and PDFs, leading to inefficiencies, tracking difficulties, and approval delays.

As clinical trials evolve toward decentralized and adaptive designs, improving protocol development with structured authoring tools, real-time collaboration platforms, and automation will be crucial to accelerating trial timelines, enhancing regulatory compliance, and improving data integrity.

ELABORATION ON CHALLENGES IN TRADITIONAL PROTOCOL DEVELOPMENT

As introduced above despite following a structured workflow, traditional clinical trial protocol development presents significant challenges that hinder efficiency, increase costs, and introduce risks to data integrity. While a protocol serves as the foundation of a clinical trial, the traditional methods of authoring, reviewing, and approving protocols often create inefficiencies that impact downstream processes. The reliance on static document formats necessitates manual data entry, version control management, and document distribution across multiple stakeholders and downstream systems, increasing the potential for errors and delays.

Additionally, the lack of integration between protocol development and other clinical trial systems exacerbates inefficiencies. Essential trial setup activities—such as designing Case Report Forms (CRFs), configuring clinical trial databases, and ensuring alignment across EDC systems—require extensive manual translation of protocol content into structured formats suitable for trial execution. These inefficiencies contribute to increased costs, prolonged trial timelines, and potential rework.

1. Complexity and Fragmentation in Protocol Design
While MS Word allows for flexibility in drafting and editing, it also introduces inefficiencies when protocols must be replicated across various clinical trial systems, including EDC, CTMS, and regulatory submission platforms. The manual transference of protocol content across these systems creates several challenges:

- **Redundant Data Entry and Increased Risk of Human Error:** Since protocols are not inherently structured for direct integration with downstream clinical trial systems, information must be manually extracted and re-entered multiple times. This duplication introduces a high risk of transcription errors, inconsistencies, and misinterpretations.
- **Version Control Difficulties:** As protocols undergo multiple revisions, ensuring that all stakeholders reference the most recent version is challenging. Investigators, clinical operations teams, and regulatory authorities may work with different versions of the protocol, leading to discrepancies in trial execution.
- **Extended Timelines Due to Inefficient Document Handling:** Protocol development and approval cycles can take months due to manual processes. Each revision requires time-consuming coordination between teams, and since approvals often occur sequentially rather than concurrently, delays accumulate (Califf et al., 2021).

Without automated data flow between protocol documents and downstream trial systems, these inefficiencies persist throughout the clinical trial lifecycle, impacting trial startup and execution.

2. Regulatory Delays and Approval Bottlenecks
Regulatory agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Medicines and Healthcare Products Regulatory Agency (MHRA) impose stringent requirements on clinical trial protocols to ensure participant safety and scientific validity. However, due to the lack of standardized protocol templates, many submissions require extensive back-and-forth revisions before regulatory approval is granted.

- **Multiple Revision Requests Due to Non-Standardized Protocols:** Regulatory bodies often request modifications to protocol sections such as study endpoints, eligibility criteria, safety monitoring, and statistical analysis plans. These iterative reviews introduce delays and administrative burden, as sponsors must manually adjust and resubmit documents (Getz, 2021).

- **Financial Impact of Protocol Amendments:** Studies show that the cost of protocol amendments is substantial, with a single amendment in a Phase III trial costing an average of $535,000, adding significant financial strain to sponsors (Getz, 2021). These costs are compounded when multiple amendments are required before regulatory approval is granted.
- **Inefficiencies in Communication Between Stakeholders:** Traditional protocol submissions often involve email exchanges, PDF attachments, and manual tracking of comments, which slow down decision-making. A more integrated, structured approach to protocol authoring—where data is directly linked to regulatory requirements—could streamline these interactions.

Regulatory approval is a critical milestone in clinical trial initiation, and inefficiencies in this phase exacerbate delays in patient enrollment, site activation, and trial execution.

3. Challenges in Downstream Processes: CRF Development and Clinical Trial Database Setup

While protocol development is the foundation of a clinical trial, significant inefficiencies arise in translating protocol content into operational trial components such as CRFs and clinical trial databases. These processes, which should seamlessly flow from protocol design, often require manual interpretation and re-entry of information, leading to errors, inconsistencies, and rework.

3a. Case Report Form (CRF) Development

CRFs serve as the primary data collection tool in clinical trials, ensuring that all relevant study data is captured in a structured and consistent manner. However, despite the CRF being directly informed by the protocol, the process of CRF development is often highly manual and inefficient:

- **Manual Extraction of Protocol Data:** Since protocols are authored in Word or PDF formats, CRF designers must manually review the protocol and extract relevant data points while comparing it to industry and internal standards (e.g., CDISC). This approach introduces a risk of misinterpretation or omission of critical study parameters.
- **Repetition of Data Entry:** The same eligibility criteria, study visit schedules, and outcome measures defined in the protocol must be re-entered into the CRF design templates, leading to inefficiencies and a higher probability of errors.
- **Versioning Challenges Between Protocol and CRFs:** If protocol amendments occur, the corresponding updates must be manually reflected in the CRF, creating potential mismatches between what is stated in the protocol and what is recorded in the CRFs used at trial sites (Rosenblatt et al., 2019).

A structured approach to protocol authoring, where protocol elements are stored in machine-readable formats rather than static documents, could facilitate automated CRF generation, reducing manual effort and the risk of discrepancies.

3b. Clinical Trial Database Setup and Integration

The process of setting up the clinical trial database—which collects and manages patient data—also faces challenges due to the manual nature of protocol-to-database translation.

- **Time-Consuming Database Configuration:** Setting up an EDC system requires defining study visit structures, data fields, and validation rules based on the protocol. However, since protocols are not designed for direct database integration, study teams must manually configure these parameters, leading to inefficiencies.
- **Risk of Misalignment Between Protocol and Database Logic:** If visit windows, dosing schedules, or assessment time points are inconsistently interpreted during database setup, discrepancies can arise, impacting data quality and regulatory compliance.

- **Manual Data Entry into CTMS:** Protocol details must also be manually input into CTMS platforms for tracking site activities, enrollment progress, and trial finances. This duplication of effort further extends trial startup timelines (Rosenblatt et al., 2019).

A more integrated digital approach—where structured protocol data is automatically mapped to CRFs, EDC databases, and CTMS platforms—could eliminate inefficiencies, reduce setup time, and improve data consistency across trial systems.

Summary of Challenges in Traditional Protocol Development
The traditional process of clinical trial protocol development is fraught with inefficiencies that extend beyond protocol authoring and approval. While regulatory delays and protocol complexity are significant challenges, the downstream impact on CRF development and clinical trial database setup further exacerbates inefficiencies.

The reliance on static, unstructured documents forces teams to manually extract, re-enter, and interpret protocol information across multiple systems, introducing errors, inconsistencies, multiple iterations, and unnecessary administrative burden. This manual approach slows down clinical trial startup, increases the risk of protocol-to-database misalignment, and leads to costly rework.

To address these challenges, the adoption of structured protocol authoring tools, automated CRF generation systems, and seamless EDC integration technologies will be critical. Modernizing these processes can accelerate trial timelines, improve data integrity, and reduce unnecessary manual labor, ultimately enhancing the efficiency of clinical research.



Reproduced from PHUSE Paper “DS03: Digital Protocol Vision… How Digital Information Can Transform and Automate Our Processes” (Qubeck, 2024).

UNLOCKING THE PROTOCOL: THE EPROTOCOL VISION

eProtocol represents the shift from a static, document-based approach to a dynamic, automated system that integrates protocol management into the entire clinical trial lifecycle. At the core of eProtocol is the concept of a “Machine Readable and Machine Actionable” content that can drive downstream activities such as study setup, data collection, and analysis. By digitizing and structuring protocol data, eProtocol facilitates the automation of processes that were once manual, ensuring consistency, reducing redundancy and errors, while accelerating the trial timelines.

As described, the vision for eProtocol goes beyond just automating protocol design. It aims to create a fully integrated ecosystem, where protocol data is central to every phase of the trial—from planning and execution to regulatory submission. With eProtocol, trial teams no longer work in silos; instead, they leverage centralized, consistent data to drive collaboration, decision-making, and consistency with downstream system configurations.

How SPA and MDR Support the eProtocol

While eProtocol is the foundation, its true potential is unlocked when the SPA tool is integrated with other advanced tools such as MDR, CDR, and SCE. These tools not only address specific needs in clinical trial management but also can work together to create a seamless, end-to-end solution for trial teams.

Structured Protocol Authoring (SPA)

SPA tools address the traditional protocol challenges by transforming protocol development into a standards-driven, structured, and digital process that ensures consistency, reusability, and integration with downstream clinical systems.

At its core, SPA enables the creation of structured protocol templates that eliminate redundancy and enforce consistency across studies. By capturing protocol content in a machine-readable format, SPA allows trial teams to generate, manage, and modify protocols efficiently, ensuring that critical study design elements—such as objectives, endpoints, inclusion/exclusion criteria, and schedules of activities—are clearly defined, interlinked, and validated against industry standards. This structured approach reduces errors, minimizes manual effort, and enhances collaboration among clinical teams, medical writers, and regulatory reviewers. Additionally, SPA improves compliance by ensuring that protocol documents align with established Clinical Data Interchange Standards Consortium (CDISC) guidelines, reducing the risk of inconsistencies between protocol definitions and regulatory submissions.

A well-designed SPA solution should offer several key capabilities. It must allow for the reuse of protocol elements from prior studies, reducing the time and effort needed to develop new protocols while ensuring alignment with regulatory and clinical best practices. It should integrate seamlessly with a Metadata Repository (MDR) to enforce CDISC-compliant data structures, ensuring that protocol content remains standardized across studies. Additionally, it must enable the document generation of Clinical Development Plans (CDPs) and Study Protocols in multiple formats, including Microsoft Word, PDF, and structured CDISC-compliant exports. The application should also support regulatory submissions by incorporating industry-standard templates, such as TransCelerate's Common Protocol Template (CPT) and the NIH-FDA Clinical Trial Protocol Template, ensuring consistency and adherence to regulatory expectations. Furthermore, users should be able to compare protocol elements against benchmark studies, allowing them to align study designs with regulatory and clinical best practices (Giriraj, 2023).

Beyond ensuring consistency and compliance, SPA plays a crucial role in enhancing collaboration across clinical teams. SPA streamlines multiple review cycles across various stakeholders by enabling real-time collaboration, allowing medical writers, clinical teams, and regulatory reviewers the ability to edit and review protocol documents efficiently while maintaining structured study design integrity. By ensuring that protocol development occurs in a controlled, collaborative environment, SPA reduces versioning errors, improves document traceability, and enhances overall study planning efficiency.

Security, compliance, and usability are also critical factors for a successful SPA solution. An effective platform must include audit trails, version control, and role-based access management to track changes, maintain regulatory transparency, and protect proprietary study content. Given the sensitive nature of clinical trial data, SPA should offer enterprise-grade security features, ensuring that only authorized users can access, modify, or approve study protocols. The ability to enforce controlled access at multiple levels—ranging from study teams to regulatory bodies—is essential in maintaining data integrity while facilitating efficient document management.

The benefits of SPA are extensive. By accelerating study planning, it reduces the time required to draft protocols while enhancing quality and consistency through structured, standardized templates. Its ability to enforce regulatory standards and maintain a single source of truth for study protocols significantly improves regulatory readiness. The platform's user interface (UI) enhances usability, allowing medical writers, clinical teams, and regulatory reviewers to collaborate efficiently within a familiar interface. Additionally, SPA provides a structured approach to capturing and managing protocol metadata, ensuring seamless integration with other clinical trial systems, such as electronic data capture (EDC) and clinical trial management systems (CTMS). This interoperability minimizes discrepancies between protocol definitions and study execution, reducing costly amendments and protocol deviations.

The impact of SPA extends beyond individual protocol development. It fosters a more efficient, scalable, and standardized approach to clinical research by ensuring that every protocol adheres to best practices, regulatory guidelines, and industry standards. By reducing duplication, automating compliance checks, and integrating structured study designs with downstream trial systems, SPA helps organizations streamline the entire clinical trial lifecycle, from study initiation to regulatory submission.

Several solutions in the industry exemplify these capabilities, with Sycamore SPA being a strong example. Sycamore SPA is a cloud-based, collaborative protocol authoring environment that enables organizations to capture structured protocols, integrate with MDR for metadata-driven study design, synchronize with medical writing tools, while providing downstream integrations and components for CRF builds, CTMS, EDC, etc. (Sycamore Informatics, 2025). By supporting benchmark comparisons, structured protocol reuse, and CDISC-compliant exports, it aligns with the broader vision of SPA—enhancing efficiency, regulatory readiness, and study execution quality. Sycamore SPA also facilitates the generation of CDPs and Clinical Trial Protocols in multiple formats, ensuring seamless interoperability between protocol authoring and study execution systems.

By adopting Structured Protocol Authoring (SPA), organizations can improve protocol development efficiency, ensure consistency across studies, and accelerate the transition from protocol design to study execution. Whether through proprietary solutions or commercially available platforms like Sycamore SPA, this structured approach represents a fundamental shift in how clinical trials are planned and executed. By transforming protocol development into a standardized, collaborative, and digital-first process, SPA enables clinical research teams to reduce costs, minimize delays, and improve overall trial outcomes (Giriraj, 2023).

Metadata Repository (MDR)

An MDR serves as a central hub for managing trial metadata, ensuring that data definitions remain consistent, accurate, and synchronized across all systems. By leveraging an MDR, organizations can eliminate redundancy, enhance interoperability, and accelerate study build processes—significantly improving the efficiency of eProtocol management from design through execution (Giriraj, 2023).

An effective eProtocol system relies on structured, standards-driven metadata that defines essential study parameters, including protocol IDs, study titles, eligibility criteria, endpoints, schedules of activities, and other critical elements. Traditional approaches to protocol management often involve manual data entry, disconnected systems, and redundant processes, leading to inconsistencies, errors, and inefficiencies. MDR automates these processes by providing a single, authoritative source for trial metadata, ensuring that all protocol information is centrally stored, version-controlled, and seamlessly integrated with downstream systems.

By automating metadata-driven protocol development, MDR eliminates duplicate data entry, reduces transcription errors, and ensures real-time synchronization across EDC, CDRs, SCEs, and regulatory submission systems. Through automated workflows, MDR facilitates protocol standardization, metadata reuse, and instant validation against industry best practices, significantly accelerating study startup timelines and improving overall trial efficiency.

Capabilities Required in an MDR for eProtocol Automation

To effectively support eProtocol automation, an MDR must possess several key capabilities:

> **1. Centralized Metadata Management**
> The MDR must capture, store, and manage metadata definitions across all clinical trial phases, ensuring data integrity and consistency. It should maintain structured relationships between different metadata models, allowing seamless mapping between protocol design, study execution, and regulatory reporting.
>
> **2. Automated Metadata Governance and Compliance**
> MDR must ensure compliance with industry standards, such as CDISC SDTM, ADaM, and controlled terminologies, while allowing flexibility for company-specific metadata models. Built-in audit trails, version control, and governance workflows ensure that changes to study metadata are fully traceable, reviewed, and approved before implementation.
>
> **3. Metadata-Driven Study Build and Automation**

An MDR should allow bulk import and export of metadata for integration with existing study designs and regulatory requirements. It must automate EDC study builds by dynamically generating form structures, data collection elements, and study instance metadata (SIM). The system should provide impact analysis tools to assess the effects of protocol changes across study models before implementation.

4. Seamless Interoperability with Clinical Trial Systems
An MDR should provide bi-directional metadata synchronization with systems such as CTMS, EDC, CDR, and SCE, enabling seamless data flow between protocol design, execution, and analysis. It must integrate with SPA solutions to pull metadata-driven protocol definitions, ensuring that eProtocol systems remain compliant with clinical and regulatory standards.

5. AI/ML-Driven Automation and Conformance Checking
MDR should leverage AI and Machine Learning algorithms to auto-generate study instance metadata, ensuring faster, more accurate study builds. Intelligent conformance-checking modules should automatically validate study metadata against internal and industry standards, reducing the need for manual validation.

5. Traceability, Versioning, and Lifecycle Management
The MDR must track all metadata changes over time, providing a clear version history of study designs, protocol modifications, and compliance updates. Users should have access to impact analysis dashboards, allowing them to preview changes and visualize downstream effects before approving metadata modifications.

An example of a MDR solution that is integrated into and fully supports the eProtocol, is the Sycamore MDR. It enables clinical trial teams to define, govern, and automate clinical trial metadata with unparalleled efficiency. Sycamore MDR manages the relationships between different study models, provides bi-directional metadata movement across systems, and accelerates EDC build and statistical programming workflows. With its AI/ML-powered Conformance Checking Module, Sycamore MDR ensures metadata compliance while allowing real-time validation and governance (Sycamore Informatics, 2025).

The Impact of MDR on Clinical Trial Efficiency
Adopting and integrating MDR and eProtocol systems organizations can achieve faster study builds, improved protocol consistency, and enhanced regulatory compliance. This combination provides a fully automated framework that eliminates redundancy, enhances metadata reusability, and ensures seamless interoperability across the clinical trial ecosystem. The ability to trace, version, and lifecycle-manage study metadata makes it powerful for maintaining regulatory compliance and operational efficiency. Incorporating MDR into eProtocol workflows is no longer just a best practice—it is a strategic necessity for modern clinical research organizations aiming to optimize trial efficiency, ensure compliance, and accelerate the delivery of new therapies to patients.

Digital Data Flow (DDF) Initiative: The Future of Structured Protocol Authoring

TransCelerate BioPharma Inc.'s Digital Data Flow (DDF) initiative represents a fundamental transformation in how clinical trial protocols are developed, structured, and executed. By adopting a data-centric approach, the DDF initiative enables automated workflows, interoperability, and real-time data exchange between sponsors, third-party providers, clinical sites, and regulatory agencies.

At the core of this initiative is the Unified Study Definitions Model (USDM), developed in collaboration with CDISC. The USDM standardizes the way protocol data is structured and shared across the clinical trial lifecycle, facilitating the automation of study configuration, regulatory submissions, and downstream clinical trial activities. By establishing a common data model, the USDM ensures that clinical trial metadata is consistent, machine-readable, and easily integrated with other study systems—a crucial step in eliminating redundancies and reducing study startup timelines.

From Document-Centric to Data-Centric: The DDF Approach

As described above, traditional clinical trial processes often lead to inconsistencies, delays, and inefficiencies as data must be re-entered and re-validated across multiple systems. The DDF initiative replaces this fragmented approach with a structured, digital workflow, where protocol data is automatically generated, validated, and synchronized across all trial systems. This shift accelerates study readiness while minimizing human errors. By implementing automated study asset creation, DDF ensures that study systems, such as EDC, eTMF (electronic Trial Master File), and Safety Systems, can be pre-configured and validated using structured metadata from the USDM. This enables automated study builds, streamlined protocol amendments, and real-time protocol compliance monitoring, all while maintaining alignment with regulatory expectations.

DDF and SPA

An SPA solution built on the principles of Digital Data Flow enables clinical trial sponsors to adopt a fully digital protocol development framework as it ensures that clinical protocols are machine-readable, interoperable, and directly linked to downstream study execution systems. A modern SPA solution aligned with DDF principles should be able to:

- **Support USDM and CDISC standards** to ensure data consistency across clinical trials.
- **Enable real-time study metadata updates**, reducing reliance on manual protocol amendments.
- **Automate protocol validation** by ensuring compliance with industry and regulatory standards.
- **Seamlessly integrate with MDRs, EDC, and other clinical systems** to enable automated study builds.
- **Enhance collaboration** across sponsors, CROs, and sites by allowing real-time access to structured protocol data.

The Industry’s Adoption of DDF and Its Impact on Clinical Trials

In 2024, TransCelerate BioPharma highlighted key advancements in the DDF initiative, demonstrating its potential to revolutionize protocol standardization, data interoperability, and clinical trial efficiency. The adoption of DDF-based workflows is expected to:

- **Significantly reduce study cycle times**, expediting the transition from protocol development to execution.
- **Enhance regulatory compliance** by ensuring protocols are built using structured, validated data models.
- **Enable automated and dynamic study readiness**, reducing the manual burden on study teams.
- **Improve data quality and integrity** by maintaining a single, authoritative source for protocol metadata.

By embracing Digital Data Flow, organizations can transition toward faster, more efficient, and higher-quality clinical trials. The integration of DDF principles into modern SPA solutions ensures that structured protocol authoring is not just a documentation exercise—but a fully digital, data-driven process that aligns with the future of clinical research.

Example eProtocol Information Flow from SPA to SCE
The following graphic illustrates the core concepts discussed throughout this article, demonstrating the flow of information across key clinical trial systems. It visually represents how structured protocol data moves seamlessly from protocol authoring to metadata management, clinical data storage, and statistical computing environments, ensuring interoperability, automation, and efficiency in clinical research.

At the beginning of the process, SPA enables study teams to create digital, standardized protocols. The structured protocol elements are sourced (in part) and stored in the MDR, which ensures consistency and alignment by managing standardized study metadata. From MDR, the study metadata integrates with the CDR, where clinical data is stored and compliance checks executed. Finally, SCE can leverage the eProtocol information by executing relevant transformations and analyses. This interconnected system illustrates the power of structured data and metadata-driven automation, reinforcing how eProtocol, Digital Data Flow (DDF), and industry standards (e.g., CDISC, ICH M11) work together to streamline trial execution. By ensuring real-time data exchange and reducing manual interventions, these integrated systems enhance compliance, reduce errors, and accelerate study timelines.



(Sycamore Informatics, 2025)

INEVITABLE ADOPTION OF EPROTOCOL: A TRANSFORMATION IN CLINICAL TRIALS

The adoption of eProtocol is not just an emerging trend but an inevitable transformation in clinical research. Driven by the strive for operational efficiencies, industry-wide standardization, and the increasing reliance on automation and artificial intelligence, the transition from traditional, document-centric protocol development to structured, machine-readable formats is unavoidable. Clinical trial protocols, once managed through static documents, are now evolving into digital, structured workflows that seamlessly integrate with downstream systems.

Adding urgency to this shift is the global labor shortage in clinical research. As demand for trials increases while the available workforce shrinks, organizations must rethink their approach to clinical trial execution. Traditional methods that rely on manual processes, redundant documentation, and inefficient workflows are no longer sustainable. To remain competitive and ensure continuity in clinical research, companies must adopt automation-driven solutions that streamline protocol development, optimize resources, and enhance overall efficiency.

Regulatory Pressures and Compliance Requirements
Regulatory agencies worldwide are setting the stage for a future in which clinical trial protocols must be structured, machine-readable, and digitally integrated. The FDA, EMA, and ICH have been progressively tightening their expectations for electronic submissions, ensuring that protocol content adheres to standardized formats for improved

efficiency, consistency, and regulatory compliance. The FDA's Digital Health Strategy encourages the use of structured data for regulatory submissions, reducing inefficiencies associated with manual review processes. Similarly, the ICH M11 Harmonized Guideline for Clinical Protocols aims to establish a globally consistent approach to protocol development through structured data models, making regulatory submissions more transparent and efficient. Organizations such as CDISC have already laid the foundation for this transformation with standards like SDTM, ADaM, and Define.xml, which have become essential for regulatory submissions.

The Unsustainability of Manual Processes in a Resource-Constrained Industry
Traditional protocol development, which relies on manually edited documents, is no longer sustainable. The process requires extensive review cycles, cross-functional collaboration, and redundant data entry across multiple clinical systems, leading to delays and increased operational costs. With ongoing labor shortages, organizations face additional pressure to streamline workflows and maximize efficiency.

Protocol amendments further compound these challenges. According to a study by the Tufts Center for the Study of Drug Development (Tufts CSDD), 57% of clinical trial protocols require at least one substantial amendment, with Phase II and III trials experiencing amendment rates as high as 77% and 66%, respectively. These amendments add an average of three unplanned months to trial timelines, increasing costs and straining already overburdened clinical teams (Tufts CSDD, 2021). The delays often stem from inconsistencies between protocol documents and the downstream systems that rely on them, requiring time-consuming reconciliation across EDC, CTMS, regulatory submission platforms, and safety databases.

eProtocol eliminates these inefficiencies as changes can be dynamically reflected across integrated systems, reducing the burden of manual intervention and minimizing compliance risks. By automating protocol authoring and ensuring interoperability, eProtocol allows clinical teams to operate more efficiently, keeping trials on schedule while making better use of limited resources.

Industry-Wide Standardization and the Digital Data Flow Initiative
The inevitability of eProtocol adoption is further reinforced by industry-wide standardization initiatives led by organizations such as TransCelerate BioPharma and CDISC. The DDF initiative is a prime example of how the industry is moving toward full automation, enabling protocol data to flow seamlessly across clinical trial systems. At the heart of this initiative is the USDM, which establishes a standardized framework for structuring protocol metadata. This ensures that study definitions can be shared, reused, and integrated across sponsors, CROs, and regulatory agencies. As these industry-wide frameworks become the norm, organizations that fail to adopt eProtocol will struggle with inefficiencies, data silos, and non-compliance. With a shrinking workforce and increasing regulatory expectations, the industry can no longer afford duplicative data entry, document versioning issues, and disconnected workflows. The only viable path forward is structured, automated protocol management.

The Rise of Automation and Artificial Intelligence in Clinical Trials
The increasing role of artificial intelligence, machine learning, and automation in clinical research further reinforces the need for structured, machine-readable protocols. AI-driven tools are transforming clinical trial operations by automating study build processes, optimizing data validation, and ensuring real-time regulatory compliance. However, these technologies can only function effectively if protocols are structured and digitally integrated from the outset. Traditional, unstructured documents do not support automation and require additional time-consuming steps before they can be processed by AI-driven tools. A well-implemented eProtocol system facilitates real-time metadata synchronization, reducing the likelihood of protocol deviations and ensuring that study parameters remain aligned across all systems.

The Future of Clinical Trials is Digital, Automated, and Resource-Efficient
The adoption of eProtocol is inevitable. The clinical research industry is undergoing a fundamental transformation, driven by regulatory expectations, digital standardization, automation, and labor shortages. Traditional, document-heavy approaches to protocol management are no longer sustainable in an era where compliance, speed, and efficiency are critical for success. By implementing structured protocol authoring, metadata-driven automation, and the Digital Data Flow initiative, organizations can accelerate study execution, reduce dependence on manual labor, and improve overall clinical trial efficiency. Those that embrace eProtocol today will be positioned as industry leaders,

while those that delay adoption risk falling behind in an increasingly competitive and resource-constrained environment. The future of clinical trials is digital, structured, and automated. With an industry facing labor shortages and rising regulatory expectations, the time for eProtocol adoption is now.

CONCLUSION

The clinical trial industry can no longer afford to rely on outdated, document-heavy workflows that delay study execution and introduce compliance risks. eProtocol represents the future—a fully digital, structured, and automated approach to protocol management that integrates seamlessly with regulatory requirements, clinical trial execution systems, and global data standards. By implementing Structured Protocol Authoring (SPA), Metadata Repositories (MDR), and TransCelerate's Digital Data Flow (DDF) initiative, clinical research organizations can:

- Reduce protocol development timelines by automating study builds.
- Eliminate inefficiencies caused by redundant data entry and version control issues.
- Ensure real-time synchronization of protocol data across all trial systems.
- Enhance compliance with global regulatory standards (CDISC, ICH, FDA, EMA).

The adoption of eProtocol is no longer optional—it is a strategic necessity. As the industry moves toward a digital-first clinical trial ecosystem, organizations that fail to modernize will face increasing inefficiencies, rising costs, and delays in bringing new therapies to market. Now is the time to embrace structured protocol automation and unlock the full potential of eProtocol-driven clinical research.

REFERENCES

- Applied Clinical Trials. 2019. "Characterizing Clinical Data Management Challenges and Their Impact." Applied Clinical Trials. https://www.appliedclinicaltrialsonline.com/view/characterizing-clinical-data-management-challenges-and-their-impact.
- BioSpace. 2023. "Navigating the Challenges of Clinical Trial Design." BioSpace. https://www.biospace.com/article/navigating-the-challenges-of-clinical-trial-design/.
- CDISC. 2025. "Digital Data Flow, USDM." CDISC. https://www.cdisc.org/ddf.
- Chan, A.-W., J. M. Tetzlaff, D. G. Altman, A. Laupacis, P. C. Gøtzsche, K. Krleža-Jerić, A. Hróbjartsson, H. Mann, K. Dickersin, J. A. Berlin, C. J. Doré, W. R. Parulekar, W. S. Summerskill, T. Groves, K. F. Schulz, H. C. Sox, F. W. Rockhold, D. Rennie, and D. Moher. 2013. "SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials." Annals of Internal Medicine 158 (3): 200–207. https://doi.org/10.7326/0003-4819-158-3-201302050-00583.
- Getz, Kenneth A., Rachael Zuckerman, Richard Kaitin, and Ken Kaitin. 2016. "The Impact of Protocol Amendments on Clinical Trial Performance and Cost." Therapeutic Innovation & Regulatory Science 50 (4): 436–441. https://journals.sagepub.com/doi/10.1177/2168479016632271.
- Giriraj, Suhas. 2023. "Structured Protocol Authoring (SPA) – A Catalyst for Clinical Protocol Development." PHUSE Paper SD02. https://phuse.s3.eu-central-1.amazonaws.com/Archive/2023/Connect/US/Florida/PAP_SD02.pdf.
- ICH. 2022. "ICH M11 Guideline, Clinical Study Protocol Template and Technical Specifications - Scientific Guideline." European Medicines Agency (EMA). https://www.ema.europa.eu/en/ich-m11-guideline-clinical-study-protocol-template-and-technical-specifications-scientific-guideline.
- International Council for Harmonisation (ICH). 2016. E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1). https://www.ich.org/page/efficacy-guidelines.
- Lindus Health. 2023. "A Comprehensive Guide to Designing a Clinical Trial Protocol for Beginners." Lindus Health. https://www.lindushealth.com/blog/a-comprehensive-guide-to-designing-a-clinical-trial-protocol-for-beginner.
- Lindus Health. 2023. "Clinical Trial Protocol Development Guide." Lindus Health. https://www.lindushealth.com/blog/a-guide-to-clinical-trial-protocol-development.

- Qubeck, William (2024). PHUSE Paper DS03: Digital Protocol Vision … How Digital Information Can Transform and Automate Our Processes. https://phuse.s3.eu-central-1.amazonaws.com/Archive/2024/Connect/US/Bethesda/PRE_DS03.pdf.
- Sycamore Informatics. 2025. "Structured Protocol Authoring." Sycamore Informatics. https://www.sycamoreinformatics.com/spa.
- TransCelerate Biopharma Inc. 2022. Digital Data Flow Overview. YouTube. https://www.youtube.com/watch?v=082onW7jhe4.
- TransCelerate Biopharma Inc. 2024. Digital Data Flow (DDF) Solution Showcase. YouTube. https://www.youtube.com/watch?v=gmgSPpcBQi0.
- TransCelerate Biopharma Inc. 2025. Digital Data Flow. https://www.transceleratebiopharmainc.com/initiatives/digital-data-flow.
- TransCelerate Biopharma Inc. 2025. Digital Data Flow Playlist. YouTube. https://www.youtube.com/playlist?list=PLMXS-Xt7Ou1KNUF-HQKQRRzqfPQEXWb1u.
- Tufts Center for the Study of Drug Development. 2021. "Acknowledging the Cycle Time Impact of Protocol Amendments." Applied Clinical Trials, August 1, 2021. https://www.appliedclinicaltrialsonline.com/view/acknowledging-cycle-time-impact-protocol-amendments.
- U.S. Food and Drug Administration (FDA). 2014. "IND Applications for Clinical Investigations: Clinical Protocols." https://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-applications-clinical-investigations-clinical-protocols. https://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-applications-clinical-investigations-clinical-protocols.
- U.S. Food and Drug Administration (FDA). 2022. "M11 Template: Clinical Electronic Structured Harmonised Protocol." https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m11-template-clinical-electronic-structured-harmonised-protocol.
- U.S. Food and Drug Administration (FDA). 2023. Clinical Trials Guidance Documents. https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/clinical-trials-guidance-documents.
- University of California, San Francisco. 2022. Clinical Research Resource HUB: Protocol Development. https://hub.ucsf.edu/protocol-development.

CONTACT INFORMATION

Contact the author at:

Author Name: Bill Qubeck
Company: Sycamore Informatics
Email: Bill.Qubeck@SycamoreInformatics.com
Website: https://www.sycamoreinformatics.com/

Author Name: Suhas Giriraj
Company: Sycamore Informatics
Email: Suhas.Giriraj@SycamoreInformatics.com
Website: https://www.sycamoreinformatics.com/